Financial Ratios Laboratorios Farmaceuticos Rovi, S.A. OTC Markets
Stocks
LABF.F
ES0157261019
Pharmaceuticals
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 65.86 USD | -27.31% |
|
-.--% | - |
| 05-13 | Spanish stocks - Factors to watch on May 13 | RE |
| 05-09 | Laboratorios Farmaceuticos Rovi, S.A., Q1 2026 Earnings Call, May 06, 2026 |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 17.38 | 19.68 | 16.34 | 13.69 | 12.11 | |||||
Return on Total Capital | 22.89 | 27.88 | 22.81 | 17.12 | 14.49 | |||||
Return On Equity % | 36.25 | 40.24 | 31.98 | 24.33 | 22.33 | |||||
Return on Common Equity | 36.25 | 40.3 | 32.16 | 24.63 | 22.72 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 58.56 | 62.67 | 58.27 | 61.24 | 63.43 | |||||
SG&A Margin | 15.92 | 15.9 | 17.72 | 20.72 | 21.58 | |||||
EBITDA Margin % | 30.55 | 33.18 | 28.69 | 26.14 | 26.3 | |||||
EBITA Margin % | 28.39 | 31.33 | 26.74 | 23.65 | 23.53 | |||||
EBIT Margin % | 28.02 | 31.03 | 26.46 | 23.4 | 23.29 | |||||
Income From Continuing Operations Margin % | 23.6 | 24.42 | 20.53 | 17.92 | 18.88 | |||||
Net Income Margin % | 23.6 | 24.42 | 20.53 | 17.92 | 18.89 | |||||
Net Avail. For Common Margin % | 23.6 | 24.42 | 20.53 | 17.92 | 18.89 | |||||
Normalized Net Income Margin | 17.76 | 19.58 | 16.61 | 14.54 | 15.42 | |||||
Levered Free Cash Flow Margin | 10.36 | 16.62 | 3.06 | 5.84 | 11.07 | |||||
Unlevered Free Cash Flow Margin | 10.44 | 16.69 | 3.13 | 6.04 | 11.28 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.99 | 1.01 | 0.99 | 0.94 | 0.83 | |||||
Fixed Assets Turnover | 3.85 | 4.12 | 3.54 | 2.83 | 2.41 | |||||
Receivables Turnover (Average Receivables) | 6.72 | 5.64 | 5.83 | 6.38 | 5.35 | |||||
Inventory Turnover (Average Inventory) | 1.14 | 1.1 | 1.07 | 0.89 | 0.88 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 2.66 | 2.12 | 2.55 | 3.13 | 3.13 | |||||
Quick Ratio | 1.35 | 1.04 | 0.83 | 0.99 | 1.51 | |||||
Operating Cash Flow to Current Liabilities | 0.78 | 0.81 | 0.57 | 0.88 | 1.03 | |||||
Days Sales Outstanding (Average Receivables) | 54.34 | 64.73 | 62.65 | 57.36 | 68.27 | |||||
Days Outstanding Inventory (Average Inventory) | 320.87 | 333.24 | 342.64 | 412.88 | 414.76 | |||||
Average Days Payable Outstanding | 104.62 | 112.85 | 115.46 | 126.96 | 138.66 | |||||
Cash Conversion Cycle (Average Days) | 270.59 | 285.13 | 289.83 | 343.28 | 344.38 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 15.53 | 13.84 | 12.04 | 19.67 | 18.04 | |||||
Total Debt / Total Capital | 13.45 | 12.16 | 10.74 | 16.44 | 15.28 | |||||
LT Debt/Equity | 14.17 | 11.4 | 9.61 | 15.6 | 13.8 | |||||
Long-Term Debt / Total Capital | 12.27 | 10.01 | 8.58 | 13.04 | 11.69 | |||||
Total Liabilities / Total Assets | 35.72 | 40.66 | 32.05 | 30.11 | 29.32 | |||||
EBIT / Interest Expense | 200.81 | 298.87 | 231.51 | 76.04 | 67.53 | |||||
EBITDA / Interest Expense | 223.25 | 324.59 | 256.23 | 87.5 | 78.74 | |||||
(EBITDA - Capex) / Interest Expense | 178.81 | 264.85 | 199.49 | 62.34 | 53.31 | |||||
Total Debt / EBITDA | 0.36 | 0.26 | 0.27 | 0.56 | 0.6 | |||||
Net Debt / EBITDA | -0.13 | -0.19 | 0.16 | 0.42 | 0.12 | |||||
Total Debt / (EBITDA - Capex) | 0.45 | 0.32 | 0.35 | 0.78 | 0.89 | |||||
Net Debt / (EBITDA - Capex) | -0.16 | -0.24 | 0.21 | 0.59 | 0.17 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 54.46 | 26.06 | 1.44 | -7.93 | -2.65 | |||||
Gross Profit, 1 Yr. Growth % | 60.18 | 34.91 | -5.68 | -3.23 | 0.83 | |||||
EBITDA, 1 Yr. Growth % | 121.13 | 38.04 | -12.28 | -16.13 | -2.04 | |||||
EBITA, 1 Yr. Growth % | 137.34 | 40.32 | -13.4 | -18.57 | -3.18 | |||||
EBIT, 1 Yr. Growth % | 142.57 | 40.85 | -13.5 | -18.58 | -3.11 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 150.71 | 30.43 | -14.71 | -19.63 | 2.55 | |||||
Net Income, 1 Yr. Growth % | 150.71 | 30.44 | -14.69 | -19.64 | 2.6 | |||||
Normalized Net Income, 1 Yr. Growth % | 149.14 | 40.22 | -13.95 | -19.4 | 3.2 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 150.63 | 35.14 | -14.25 | -16.53 | 2.73 | |||||
Accounts Receivable, 1 Yr. Growth % | 104.94 | 23.44 | -22.27 | -7.81 | 42.23 | |||||
Inventory, 1 Yr. Growth % | 8.04 | 27.08 | 8.34 | -2.37 | -12.72 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 16.98 | 18.58 | 17.68 | 13 | 15.39 | |||||
Total Assets, 1 Yr. Growth % | 27.55 | 19.93 | -8.97 | 4.02 | 14.86 | |||||
Tangible Book Value, 1 Yr. Growth % | 29.34 | 11.7 | 4.23 | 6.28 | 16.81 | |||||
Common Equity, 1 Yr. Growth % | 26.03 | 10.41 | 3.73 | 6.05 | 16.15 | |||||
Cash From Operations, 1 Yr. Growth % | 218.8 | 58.99 | -52.34 | 22.1 | 35.29 | |||||
Capital Expenditures, 1 Yr. Growth % | 2.24 | 26.11 | 6.06 | 9.9 | 10.3 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -657.51 | 105.33 | -81.34 | 75.96 | 83.48 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -695.3 | 104.38 | -80.98 | 77.6 | 82.02 | |||||
Dividend Per Share, 1 Yr. Growth % | 150.68 | 35.39 | -14.69 | -15.28 | 2.6 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 30.43 | 39.54 | 13.08 | -3.36 | -5.33 | |||||
Gross Profit, 2 Yr. CAGR % | 34.03 | 47 | 12.81 | -4.46 | -1.22 | |||||
EBITDA, 2 Yr. CAGR % | 89.05 | 74.01 | 10.04 | -14.23 | -9.36 | |||||
EBITA, 2 Yr. CAGR % | 103.03 | 81.71 | 10.23 | -16.03 | -11.21 | |||||
EBIT, 2 Yr. CAGR % | 107.93 | 84.03 | 10.37 | -16.08 | -11.18 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 97.43 | 80.84 | 5.48 | -17.2 | -9.21 | |||||
Net Income, 2 Yr. CAGR % | 97.43 | 80.84 | 5.49 | -17.2 | -9.2 | |||||
Normalized Net Income, 2 Yr. CAGR % | 108.93 | 86.1 | 9.84 | -16.72 | -8.8 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 97.03 | 83.94 | 7.71 | -15.4 | -7.4 | |||||
Accounts Receivable, 2 Yr. CAGR % | 34.58 | 59.05 | -2.04 | -15.34 | 14.51 | |||||
Inventory, 2 Yr. CAGR % | 24.33 | 17.18 | 17.34 | 2.85 | -7.69 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 17.52 | 17.77 | 18.13 | 15.32 | 14.19 | |||||
Total Assets, 2 Yr. CAGR % | 19.72 | 23.68 | 4.49 | -2.69 | 9.31 | |||||
Tangible Book Value, 2 Yr. CAGR % | 24.12 | 20.2 | 7.9 | 5.25 | 10.84 | |||||
Common Equity, 2 Yr. CAGR % | 20.87 | 17.96 | 7.02 | 4.88 | 10.99 | |||||
Cash From Operations, 2 Yr. CAGR % | 306.49 | 125.14 | -12.95 | -23.71 | 28.53 | |||||
Capital Expenditures, 2 Yr. CAGR % | 24.61 | 13.55 | 15.65 | 7.96 | 10.1 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 2.24 | 235.84 | -38.1 | -42.7 | 80.14 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 3 | 246.26 | -37.65 | -41.88 | 79.8 | |||||
Dividend Per Share, 2 Yr. CAGR % | 133.61 | 84.23 | 7.47 | -14.99 | -6.77 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 28.85 | 28.95 | 25.47 | 5.59 | -3.12 | |||||
Gross Profit, 3 Yr. CAGR % | 30.46 | 34.32 | 26.79 | 7.18 | -2.73 | |||||
EBITDA, 3 Yr. CAGR % | 94.37 | 69.78 | 38.49 | 0.52 | -10.34 | |||||
EBITA, 3 Yr. CAGR % | 119.4 | 78.99 | 41.93 | -0.35 | -11.95 | |||||
EBIT, 3 Yr. CAGR % | 125.39 | 82.08 | 43.09 | -0.27 | -11.96 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 104.52 | 71.95 | 40.76 | -3.66 | -11.08 | |||||
Net Income, 3 Yr. CAGR % | 104.52 | 71.95 | 40.77 | -3.66 | -11.07 | |||||
Normalized Net Income, 3 Yr. CAGR % | 122.73 | 82.4 | 43.91 | -0.93 | -10.55 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 99.24 | 73.7 | 42.68 | -1.06 | -9.74 | |||||
Accounts Receivable, 3 Yr. CAGR % | 36.53 | 30.76 | 25.28 | -4 | 0.64 | |||||
Inventory, 3 Yr. CAGR % | 37.29 | 25.24 | 14.15 | 10.36 | -2.63 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 23.78 | 17.87 | 17.74 | 16.39 | 15.34 | |||||
Total Assets, 3 Yr. CAGR % | 22.08 | 19.79 | 11.67 | 4.33 | 2.84 | |||||
Tangible Book Value, 3 Yr. CAGR % | 18.94 | 19.84 | 14.62 | 7.36 | 8.59 | |||||
Common Equity, 3 Yr. CAGR % | 17.89 | 17.28 | 13.01 | 6.69 | 8.51 | |||||
Cash From Operations, 3 Yr. CAGR % | 159.71 | 197.28 | 34.18 | -2.55 | -7.66 | |||||
Capital Expenditures, 3 Yr. CAGR % | 34.88 | 25.11 | 11 | 13.7 | 8.74 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 42.77 | 28.36 | 28.15 | -12.32 | -15.4 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 44.1 | 28.8 | 31.63 | -11.62 | -14.97 | |||||
Dividend Per Share, 3 Yr. CAGR % | 128.78 | 94.77 | 42.53 | -0.72 | -9.49 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 19.59 | 24.29 | 22.3 | 14.9 | 12.1 | |||||
Gross Profit, 5 Yr. CAGR % | 20.45 | 25.92 | 23.09 | 17.21 | 14.74 | |||||
EBITDA, 5 Yr. CAGR % | 43.45 | 60.57 | 54.56 | 29.2 | 16.89 | |||||
EBITA, 5 Yr. CAGR % | 50.3 | 72.55 | 66.31 | 32.24 | 17.65 | |||||
EBIT, 5 Yr. CAGR % | 51.54 | 75.64 | 69.1 | 33.57 | 18.24 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 42.46 | 63.21 | 56.93 | 28.36 | 18.11 | |||||
Net Income, 5 Yr. CAGR % | 42.46 | 63.21 | 56.93 | 28.37 | 18.13 | |||||
Normalized Net Income, 5 Yr. CAGR % | 50.48 | 71 | 67.58 | 33.3 | 19.91 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 39.17 | 60.55 | 55.75 | 30.3 | 20.02 | |||||
Accounts Receivable, 5 Yr. CAGR % | 23.42 | 31.26 | 19.55 | 9.89 | 20.86 | |||||
Inventory, 5 Yr. CAGR % | 29.51 | 32.81 | 28.93 | 15.75 | 4.86 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 17.02 | 19.34 | 21.49 | 16.84 | 16.31 | |||||
Total Assets, 5 Yr. CAGR % | 20.55 | 24.11 | 14.71 | 10.23 | 10.72 | |||||
Tangible Book Value, 5 Yr. CAGR % | 21.97 | 23.19 | 14.39 | 13.77 | 13.09 | |||||
Common Equity, 5 Yr. CAGR % | 20.76 | 22.09 | 13.41 | 12.15 | 12.2 | |||||
Cash From Operations, 5 Yr. CAGR % | 26.84 | 67.47 | 67.73 | 72.54 | 31.89 | |||||
Capital Expenditures, 5 Yr. CAGR % | 32.96 | 27.71 | 26.83 | 17.95 | 10.64 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 27.31 | 76.97 | 1.9 | -7.03 | 46.85 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 26.8 | 80.12 | 2.77 | -6.31 | 49.11 | |||||
Dividend Per Share, 5 Yr. CAGR % | 39.18 | 60.71 | 69.11 | 39.8 | 20.27 |
Select your edition
All financial news and data tailored to specific country editions
















